Abstract: Poster Presentations |


Kerry D. Griscti, BSN; Robert J. Maykut, MD; Marc Massanari, PharmD; Carlos A. Camargo, MD; Stanley J. Szefler, MD; Mark A. Brown, MD*; Christine A. Sorkness, PharmD; Farid Kianfard, PhD; Robert K. Zeldin, MD
Author and Funding Information

University of Arizona College of Medicine, Tucson, AZ


Chest. 2009;136(4_MeetingAbstracts):33S-b-34S. doi:10.1378/chest.109.3_Supplement.33S-a
Text Size: A A A
Published online


PURPOSE:  To characterize moderate-to-severe allergic asthma and its treatment burden in children aged 6–11 years inadequately controlled with inhaled corticosteroids.

METHODS:  474 patient/caregiver pairs from 46 centers in the U.S. and Puerto Rico are being followed in a 2-year observational study. Key inclusion criteria: ≥ 12-month asthma history, > 200 mcg fluticasone DPI daily or equivalent (with or without additional controllers), perennial aeroallergen sensitivity, total IgE ≥ 30 IU/mL and evidence of impairment and/or risk. Data collection includes: patient and family atopic disease history; baseline aeroallergen sensitivities; co-morbid disease history; corticosteroid burden; asthma control; environment; healthcare utilization for asthma exacerbations requiring oral corticosteroids; patient/caregiver quality of life assessment; and patient/caregiver lost days of school/work.

RESULTS:  Mean patient age (± SD) 8.7 years (1.64); 67% male; 58% caucasian and 26% black. 39% reported ≥ 1 asthma exacerbation in the 3 months prior to enrollment. Of these, 61% required treatment with an oral corticosteroid (OCS) and 13% of this subset went to the emergency room. 80% reported history of 1 or more allergic co-morbidities and 78% reported concomitant seasonal allergies. Median (interquartile range) average total daily unadjusted dose of inhaled corticosteroid in the 3 months prior to baseline was 320 (324) mcg/day. The mean (± SD) Childhood Asthma Control Test score was 19 ± 4.3.

CONCLUSION:  Despite receiving asthma treatment at doses indicated by NIH guidelines (EPR3), this cohort remains symptomatic, with frequent exacerbations These children have a high incidence of allergic co-morbidities, self-reported limitations in activity and experience a suboptimal level of control. Additional treatment, control and self-reported quality of life data will be analyzed throughout the study.

CLINICAL IMPLICATIONS:  This study will establish one of the largest and best characterized cohorts of school aged children with symptomatic moderate-to-severe allergic asthma. The study results will allow for a greater understanding of the disease burden and unmet needs of these children and their caregivers.

DISCLOSURE:  Mark Brown, Employee I am an employee of Novartis Pharmaceuticals Corporation, the funder of this study.; No Product/Research Disclosure Information

Tuesday, November 3, 2009

12:45 PM - 2:00 PM




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543